Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies

Monica M. Mita, Alain C. Mita, Jennifer L. Moseley, Jennifer Poon, Karen A. Small, Ying Ming Jou, Paul Kirschmeier, Da Zhang, Yali Zhu, Paul Statkevich, Kamelesh K. Sankhala, John Sarantopoulos, James M. Cleary, Lucian R. Chirieac, Scott J. Rodig, Rajat Bannerji, Geoffrey I. Shapiro

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Fingerprint

Dive into the research topics of 'Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies'. Together they form a unique fingerprint.

Medicine & Life Sciences